KalVista Pharmaceuticals appoints Brian J.G. Pereira as Chairman; Martin Edwards resigns in planned transition

KalVista Pharmaceuticals, Inc.

Martin Edwards resigned as Chairman and director effective immediately; departure not due to any disagreement.
Brian J.G. Pereira appointed Chairman; previously a board member since 2019 and President & CEO of Visterra.
Annual meeting results: T. Andrew Crockett and Brian J.G. Pereira elected as Class I directors.
Deloitte & Touche ratified as auditor for FY ending April 30, 2023; advisory say-on-pay approved.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Martin Edwards

Chairman of the Board

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2022-10-13
Successor: Brian J. G. Pereira
Filed: October 17, 2022, 7:59 PM ET

On October 13, 2022, Martin Edwards, M.D., announced his resignation from his position as the Chairman of the Board of Directors (the “Board”) and as a Class III director, member of the Compensation Committee of the Board (the “Compensation Committee”) and member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) of KalVista Pharmaceuticals, Inc. (the “Company”), effective immediately.

Appointed

Brian J. G. Pereira

Chairman of the Board

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2022-10-13
Filed: October 17, 2022, 7:59 PM ET

The Board approved the appointment of Brian J. G. Pereira, M.D., as Chairman of the Board, effective upon Dr. Edwards’ resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Martin Edwards resigned as Chairman of the Board at KalVista Pharmaceuticals, Inc..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

On October 13, 2022, Martin Edwards, M.D., announced his resignation from his position as the Chairman of the Board of Directors (the “Board”) and as a Class III director, member of the Compensation Committee of the Board (the “Compensation Committee”) and member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) of KalVista Pharmaceuticals, Inc. (the “Company”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian J. G. Pereira was appointed as Chairman of the Board at KalVista Pharmaceuticals, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

The Board approved the appointment of Brian J. G. Pereira, M.D., as Chairman of the Board, effective upon Dr. Edwards’ resignation.

View on SEC.gov

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-019610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.